Scientists test 'Supercharged' immune cells against tough blood cancers
NCT ID NCT06383572
Summary
This early-stage study is testing a new cell therapy for adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or hasn't responded to other treatments. Doctors are giving patients specially engineered immune cells (called PRAME-TCR-NK cells) after a short course of chemotherapy. The main goals are to find a safe dose and see if this approach can help control these difficult blood cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.